cagrilintide and semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Cagrilintide–Semaglutide in Adults with Overweight

Chronic low-grade inflammation (inflammaging) is increasingly recognized as a driver of age-related disease, and BPC-157s ability to modulate inflammatory pathways may have broader implications for healthy aging

Advances in the understanding of oxaliplatin-induced peripheral neuropathy in mice: 7-chloro-4-(phenylselanyl) quinoline as a promising therapeutic agent

While the study was observational (meaning that causality cant be confirmed), it does add to the growing body of evidence suggesting that its worth investigating these weight-loss drugs as potential cancer prevention tools, says lead author, Professor Elizabeth McDonald

The results came even faster than what I read online about people getting GLP-1 injections at medical facilities

Anxiety afflicts 2545% of chronic liver disease patients, while depression affects a staggering 2972% (41)